Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 60

Sort by

Sort Order Select

Journal Articles

Ibrutinib as part of risk-stratified treatment for posttransplant lymphoproliferative disorder: the phase 2 TIDaL trial

Blood (2024) 144 (4): 392–401.

https://doi.org/10.1182/blood.2024023847

Published: 2024

Includes: Supplemental data

Journal Articles

The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma

Blood (2024) 143 (2): 152–165.

https://doi.org/10.1182/blood.2023021348

Published: 2024

Includes: Supplemental data

Journal Articles

Tranexamic Acid to Prevent Bleeding in Patients with Hematologic Malignancies and Severe Thrombocytopenia (TREATT trial). a Randomized Placebo-Controlled Trial

Blood (2023) 142 (Supplement 1): 702.

https://doi.org/10.1182/blood-2023-180720

Published: 2023

Journal Articles

Safety and Preliminary Efficacy of Sabestomig (AZD7789), an Anti-PD-1 and Anti-TIM-3 Bispecific Antibody, in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Previously Treated with Anti-PD-(L)1 Therapy

Blood (2023) 142 (Supplement 1): 4433.

https://doi.org/10.1182/blood-2023-180926

Published: 2023

Journal Articles

Flowrna in the Diagnosis of EBV-Related Lymphoproliferative Disease

Alexander Glover, Mark Bishton, Matthew Ahearne, Kaljit Bhuller, Steve Jones, Graham P. Collins, Lindsay George, Conal McConville, Allister Foy, Catherine Hildyard, Catherine Moore, Christopher P. Fox, Claire Shannon-Lowe

Blood (2023) 142 (Supplement 1): 3660.

https://doi.org/10.1182/blood-2023-182151

Published: 2023

Journal Articles

A First-in-Human Phase 1 Trial of NX-1607, a First-in-Class Oral CBL-B Inhibitor, in Patients with Advanced Malignancies Including DLBCL

Graham P. Collins, William Townsend, Ahmed Abdulgawad, Swathi Namburi, Anja Williams, Ana Filipa Palma DosReis, Matthew G. Krebs, Jeff Evans, Sarah P. Blagden, Ruth Plummer, Daniel Hochhauser, Adam Sharp, George Cole, Seema Rogers, Daniel Chan, Sarah Whelan, Dima El-Sharkawi

Blood (2023) 142 (Supplement 1): 3093.

https://doi.org/10.1182/blood-2023-172875

Published: 2023

Journal Articles

Initial Findings from a First-in-Human Phase 1a/b Trial of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients with Relapsed/Refractory B Cell Malignancies

Emma Searle, Francesco Forconi, Kim Linton, Alexey Danilov, Pam McKay, David Lewis, Dima El-Sharkawi, Mary Gleeson, John Riches, Sarah G. Injac, Ted Shih, Srinand Nandakumar, May Tan, Ganesh Cherala, Erin Meredith, Graham P. Collins

Blood (2023) 142 (Supplement 1): 4473.

https://doi.org/10.1182/blood-2023-179508

Published: 2023

Journal Articles

Bendamustine Plus Brentuximab Has Superior Efficacy to Brentuximab Monotherapy As Third-Line Treatment for Classical Hodgkin Lymphoma: A Real-World, Multicentre UK Analysis

Blood (2023) 142 (Supplement 1): 6173.

https://doi.org/10.1182/blood-2023-186601

Published: 2023

Journal Articles

Tackling PD1i resistance in Hodgkin lymphoma

Graham P. Collins

Blood (2023) 142 (16): 1333–1334.

https://doi.org/10.1182/blood.2023021283

Published: 2023

Journal Articles

Exploratory Analysis of Factors Influencing Efficacy and Safety of Camidanlumab Tesirine: Data from the Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)

Blood (2022) 140 (Supplement 1): 3673–3677.

https://doi.org/10.1182/blood-2022-157583

Published: 2022

Journal Articles

A Phase 1b Open-Label Study of Loncastuximab Tesirine in Combination with Other Anticancer Agents in Patients with Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (LOTIS-7)

Brian T. Hess, Graham P. Collins, Melhem Solh, Mitul Gandhi, Ying Wang, Yajuan Qin, Eric Yu, Pier Luigi Zinzani

Blood (2022) 140 (Supplement 1): 12079–12080.

https://doi.org/10.1182/blood-2022-163277

Published: 2022

Journal Articles

Five-Year Survival Results from the Remodl-B Trial (ISRCTN 51837425) Show Improved Outcomes in Diffuse Large B-Cell Lymphoma Molecular Subgroups from the Addition of Bortezomib to R-CHOP Chemoimmunotherapy

Blood (2022) 140 (Supplement 1): 1770–1772.

https://doi.org/10.1182/blood-2022-159976

Published: 2022

Journal Articles

Efficacy and Safety of Single-Agent Zandelisib Administered By Intermittent Dosing in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Final Results of the Tidal Phase 2 Study

Andrew D. Zelenetz, Wojciech Jurczak, Vincent Ribrag, Kim M. Linton, Graham P. Collins, Mark Bishton, Javier López Jiménez, Bhagirathbhai Dholaria, Andrea Mengarelli, Tycel J. Phillips, Nagendra Prasad Sungala, Henry Chan, Gerardo Musuraca, Oonagh Sheehy, Junyi Yan, Weiming Xu, Michel Azoulay, Pier Luigi Zinzani

Blood (2022) 140 (Supplement 1): 3595–3597.

https://doi.org/10.1182/blood-2022-165409

Published: 2022

Journal Articles

Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma: Real-World Outcomes in the United Kingdom

Blood (2022) 140 (Supplement 1): 7519–7521.

https://doi.org/10.1182/blood-2022-165031

Published: 2022

Journal Articles

Magrolimab in Combination with Rituximab + Chemotherapy in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Joseph Maakaron, Adam S. Asch, Leslie L. Popplewell, Graham P. Collins, Ian W. Flinn, Nilanjan Ghosh, Colin Keane, Matthew Ku, Amitkumar Mehta, Mark Roschewski, Carol O'Hear, Xuehan Ren, Bertha Villa, Indu Lal, Sonali M. Smith, Ranjana H. Advani

Blood (2022) 140 (Supplement 1): 3728–3730.

https://doi.org/10.1182/blood-2022-167772

Published: 2022

Journal Articles

Replacing Procarbazine with Dacarbazine in Escalated Beacopp Dramatically Reduces the Post Treatment Haematopoietic Stem and Progenitor Cell Mutational Burden in Hodgkin Lymphoma Patients with No Apparent Loss of Clinical Efficacy

Blood (2022) 140 (Supplement 1): 1761–1764.

https://doi.org/10.1182/blood-2022-166543

Published: 2022

Journal Articles

Durable Responses from Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study

Andrew J Davies, Josh Caddy, Katy McLaughlin, Christopher Wignall, Robert Waugh, Graham P. Collins, Louise Stanton, Geoff N Saunders, Thomas Cummin, Anna Schuh, Kirit M. Ardeshna, Andrew K. McMillan, John Radford, David John Lewis, Adam R Coleman, Gareth Griffiths, Cathy Burton, Sharon Barrans, Peter Johnson

Blood (2022) 140 (Supplement 1): 9478–9479.

https://doi.org/10.1182/blood-2022-163499

Published: 2022

Journal Articles

Epidemiological Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Use in Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) in Terms of Second Line (2L) Treatment: An Ad Hoc Analysis from the POLARIX Study

Frédéric Boissard, Hervé Tilly, Georg Lenz, Graham P. Collins, Antonio Pinto, Laurie H. Sehn, Gilles Salles, Mathilde Roussel, Leonardo Simonella, Rodrigo Ho, Jamie Hirata, Calvin Lee, Anthony Masaquel, Aino Launonen

Blood (2022) 140 (Supplement 1): 6645–6647.

https://doi.org/10.1182/blood-2022-157904

Published: 2022

Journal Articles

Increased efficacy of dual proinflammatory cytokine blockade on acute GVHD while maintaining GVT effects

Lam T. Khuat, Logan V. Vick, Cordelia Dunai, Craig P. Collins, Shyam K. More, Catherine T. Le, Chien-Chun Steven Pai, Kevin M. Stoffel, Emanual Maverakis, Robert J. Canter, Arta M. Monjazeb, Dan L. Longo, Mehrdad Abedi, Eunju Choi, Bruce R. Blazar, Maneesh Dave, William J. Murphy

Blood (2021) 138 (24): 2583–2588.

https://doi.org/10.1182/blood.2021011216

Published: 2021

Includes: Supplemental data

Journal Articles

Real World Escalated Beacopdac Delivers Similar Outcomes to Escalated Beacopp and Superior Outcomes to Response-Adapted (RATHL) ABVD, While Potentially Reducing Toxicity Compared with Escalated Beacopp

Blood (2021) 138 (Supplement 1): 877.

https://doi.org/10.1182/blood-2021-146242

Published: 2021

NARROW

Ibrutinib as part of risk-stratified treatment for posttransplant lymphoproliferative disorder: the phase 2 TIDaL trial

The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma

Tranexamic Acid to Prevent Bleeding in Patients with Hematologic Malignancies and Severe Thrombocytopenia (TREATT trial). a Randomized Placebo-Controlled Trial

Safety and Preliminary Efficacy of Sabestomig (AZD7789), an Anti-PD-1 and Anti-TIM-3 Bispecific Antibody, in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Previously Treated with Anti-PD-(L)1 Therapy

Flowrna in the Diagnosis of EBV-Related Lymphoproliferative Disease

A First-in-Human Phase 1 Trial of NX-1607, a First-in-Class Oral CBL-B Inhibitor, in Patients with Advanced Malignancies Including DLBCL

Initial Findings from a First-in-Human Phase 1a/b Trial of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients with Relapsed/Refractory B Cell Malignancies

Bendamustine Plus Brentuximab Has Superior Efficacy to Brentuximab Monotherapy As Third-Line Treatment for Classical Hodgkin Lymphoma: A Real-World, Multicentre UK Analysis

Tackling PD1i resistance in Hodgkin lymphoma

Exploratory Analysis of Factors Influencing Efficacy and Safety of Camidanlumab Tesirine: Data from the Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)

A Phase 1b Open-Label Study of Loncastuximab Tesirine in Combination with Other Anticancer Agents in Patients with Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (LOTIS-7)

Five-Year Survival Results from the Remodl-B Trial (ISRCTN 51837425) Show Improved Outcomes in Diffuse Large B-Cell Lymphoma Molecular Subgroups from the Addition of Bortezomib to R-CHOP Chemoimmunotherapy

Efficacy and Safety of Single-Agent Zandelisib Administered By Intermittent Dosing in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Final Results of the Tidal Phase 2 Study

Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma: Real-World Outcomes in the United Kingdom

Magrolimab in Combination with Rituximab + Chemotherapy in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Replacing Procarbazine with Dacarbazine in Escalated Beacopp Dramatically Reduces the Post Treatment Haematopoietic Stem and Progenitor Cell Mutational Burden in Hodgkin Lymphoma Patients with No Apparent Loss of Clinical Efficacy

Durable Responses from Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study

Epidemiological Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Use in Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) in Terms of Second Line (2L) Treatment: An Ad Hoc Analysis from the POLARIX Study

Increased efficacy of dual proinflammatory cytokine blockade on acute GVHD while maintaining GVT effects

Real World Escalated Beacopdac Delivers Similar Outcomes to Escalated Beacopp and Superior Outcomes to Response-Adapted (RATHL) ABVD, While Potentially Reducing Toxicity Compared with Escalated Beacopp

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only